Navigation Links
New molecular targets identified in some hard-to-treat melanomas provide potential treatment option

December 30, 2013 New York, NY / Los Angeles, CA: Stand Up To Cancer (SU2C), the charitable initiative supporting ground-breaking research aimed at getting new cancer treatments to patients in an accelerated timeframe, announces that Jeffrey A. Sosman, M.D., a Stand Up To Cancer Melanoma Dream Team investigator, William Pao, M.D., Ph.D., a 2009 Stand Up To Cancer Innovative Research Grant recipient and colleagues identified two novel BRAF fusions in melanomas previously considered to be negative for molecular targets, and that melanomas with these fusions were found to be potentially sensitive to anticancer drugs called MEK inhibitors, according to a study recently published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

According to Dr. Sosman, professor of medicine at Vanderbilt-Ingram Cancer Center in Nashville, Tenn., "About 35 percent of melanomas are, as of today, considered 'pan-negative,' which means they are devoid of any previously known driver mutations in the genes BRAF, NRAS, KIT, GNAQ, and GNA11." Dr. Sosman explained that at Vanderbilt, researchers have been interested in looking at patients whose tumors have none of these driver mutations, to see what their tumors do have that can be targeted therapeutically. In some cancers, two or more genes fuse erroneously to produce abnormal proteins, which can function as the "drivers" of those cancers.

"Performing a sophisticated analysis called targeted next-generation sequencing, it appears that about 8 percent of pan-negative melanomas have BRAF fusions," said Sosman. "Our results are important because they obviously suggest that there probably are other, as yet unidentified, molecular changes that make these melanomas susceptible to drugs that are available right now."

"It is very exciting to see work of Stand Up To Cancer funded researchers yield important results which advance our understanding of cancers and accelerate the science towards treatments that can make a difference for patients," stated Sherry Lansing, co-founder & member of the SU2C Council of Founders and Advisors. This research is a direct outcome from the Stand Up To Cancer Melanoma Dream Team Grant and involved the work of a Stand Up To Cancer Innovative Research Grant recipient, representing work made possible by both funding models created by SU2C to focus on groundbreaking translational research aimed at getting new therapies to patients quickly. To date, SU2C has funded $139.5 million for 11 Dream Teams and $19.4 million for 26 IRG research grants for brightest young researchers across disciplines to think out of the box and attempt to make major breakthroughs in their field with bold research projects.

In a pan-negative melanoma sample from one of their patients, Drs. Sosman and Pao and their colleagues identified a fusion between two genes, PAPSS1 and BRAF, which they called PAPSS1-BRAF. They then evaluated melanomas from an additional 51 patients, 24 of which were pan-negative. In one of these 24 pan-negative samples, they identified a second novel BRAF fusion, called TRIM24-BRAF.

The investigators conducted further studies in the laboratory and found that both BRAF fusions activated a pathway in the cancer cells called the MAPK signaling pathway. They then treated these fusion-bearing cells either with the BRAF inhibitor vemurafenib or with trametinib, a drug that inhibits a protein in the MAPK signaling pathway called MEK. They found that signaling induced by the BRAF fusions was not responsive to vemurafenib but could be inhibited by trametinib, which led them to suggest that the novel fusions they identified could make melanoma cells harboring them sensitive to MEK inhibitors.

"One of the primary objectives of Stand Up To Cancer is to accelerate the development of effective treatments to help patients. This research from Drs. Sosman and Pao advances that objective because identifying novel genetic mutations helps identify targets that might be sensitive to existing or future drug therapies," explained William G. Nelson, M.D., Ph.D., a member of the SU2C Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University in Baltimore, MD.


Contact: Jane E. Rubinstein
Rubenstein Associates, Inc.

Related medicine news :

1. The Association for Molecular Pathology releases position statement on LDTs
2. Polymer coatings based on molecular structures
3. Supercomputers help ORNL researchers identify key molecular switch that controls cell behavior
4. Mayo Clinic: Drug induces morphologic, molecular and clinical remissions in myelofibrosis
5. Maryville, Tennessee based Molecular Pathology Laboratory Network, Inc. (MPLN) Acquires the First FDA Approved High-Throughput DNA Sequencing Analyzer
6. Treatment plans for brain metastases more accurately determined with aid of molecular imaging trace
7. ATCC Examined the Importance of High-quality Controls in Assay Design and Development During the Association for Molecular Pathology (AMP) 2013 Annual Meeting
8. BCC Research Publishes A New Report On Global Markets For Molecular Imaging Devices
9. Cincinnati Childrens researchers develop first molecular test to diagnose eosinophilic esophagitis
10. Bioinformatics Market (Molecular Medicine, Agriculture, Research & Forensic) worth $7.5 Billion by 2017 - New Report by MarketsandMarkets
11. Molecular Biomarkers for Cancer Detection and Management
Post Your Comments:
Related Image:
New molecular targets identified in some hard-to-treat melanomas provide potential treatment option
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
(Date:11/27/2015)... DE (PRWEB) , ... November 27, 2015 , ... ... member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s ... an independent group of Microsoft Dynamics SL software users, partners, industry experts and ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... ... ... CBD College is proud to announce that on November 20th, ... its Diagnostic Medical Sonography program. CBD College is honored to join this very short ... universities in the state of California make the cut. CBD College is officially the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Dr. Thomas ... Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph ... that both STEMI and Sepsis conditions present in similar ways and require time-critical intervention ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
Breaking Medicine Technology: